Applications of Dextromethorphan Hydrobromide Monohydrate in Industrial Manufacturing

Our expertise in the production of Dextromethorphan Hydrobromide Monohydrate supports downstream manufacturers in tightly regulated sectors by ensuring ingredient integrity, process precision, and compliance with global standards. Below, we outline the primary industrial application scenarios and technical requirements encountered by our customers worldwide.

1. Non-Prescription Oral Liquid Antitussives

Pharmaceutical companies use our material as a key active ingredient in the formulation of over-the-counter cough suppressants, particularly in syrup or oral solution formats. Manufacturers integrate the raw material during the main active blending stage, frequently alongside sweeteners, stabilizers, and preservatives. Attention to impurity control and precise dosing ensures products meet all legal and therapeutic criteria for mass-market distribution.

Industry compliance standards

• USP 47/NF 42 Monograph for Dextromethorphan Hydrobromide
• European Pharmacopoeia (Ph. Eur.) Monograph 1532
• 21 CFR 341 (U.S. FDA OTC Cough/Cold Final Monograph)
• ICH Q3A/B Impurity Guidelines
• GMP (ICH Q7, EU GMP Part I/II)

Typical usage ratio

• Generally 0.15–0.3 mg/mL, adjusted to meet labeled dosage strength (e.g., 10–20 mg per 5 mL serving), based on regulatory limits per market

Downstream process integration

• Directly combines with aqueous syrup base post-heating and de-aeration; added after viscosity modifiers to maintain homogeneity; often involves dissolution in citric acid solution before bulk blending

Final product types

• OTC cough syrups (adult and pediatric)
• Expectorant-combination syrups
• Sugar-free oral liquids for sensitive populations

2. Solid Oral Dosage (Tablets and Lozenges) for Respiratory Relief

Contract manufacturers leverage our ingredient during tableting or lozenge manufacturing for direct inclusion in fixed-dose antitussive formats. The production process requires dry blending with diluents, binders, and direct compression, followed by strict quality checks for content uniformity and dissolution. The precise particle size and moisture profile of our product support high-speed production and batch consistency.

Industry compliance standards

• USP/NF and Ph. Eur. Monographs for solid antitussive preparations
• FDA 21 CFR 210/211 (Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs)
• WHO GMP Guidelines
• ICH Q6A Specifications for New Drug Substances and Products

Typical usage ratio

• Usually 15–30 mg per unit dose (tablet or lozenge), representing <1% w/w of total mass depending on excipient load and final product potency

Downstream process integration

• Uniform dry blend with fillers and lubricants during main granulation phase; direct compress in rotary tablet press or mold into lozenge forms; moisture content managed to prevent hydrolysis of the monohydrate salt

Final product types

• OTC antitussive tablets (uncoated and coated)
• Compressed lozenges for sore throat and cough
• Combination multiparticulate tablets with antihistamines or decongestants

3. Pediatric Antitussive Drops and Suspensions

Producers of pediatric pharmaceuticals utilize our raw material in the manufacture of low-dose, palatable drops and suspensions, where stringent control over particle size and excipient compatibility is critical. Formulators often micronize the ingredient and disperse it within stabilizer-thickened aqueous systems, balancing palatability with dose accuracy and compliance with age-group administration protocols.

Industry compliance standards

• USP/NF Pediatric Drug Monographs
• European Medicines Agency (EMA) Paediatric Regulation (EC) No 1901/2006
• WHO Model List of Essential Medicines for Children
• ICH Q2(R1) Validation of Analytical Procedures

Typical usage ratio

• 0.1–0.2 mg/mL in final pediatric drops, modulated per national pediatric maximum daily dose guidelines

Downstream process integration

• Post-micronization, integrated into pre-thickened vehicle under controlled pH, followed by homogenization; typically passes high-shear or ultrasonic mixing before filling into dropper bottles

Final product types

• Pediatric cough suppressant drops
• Oral suspensions with flavor masking

4. Modified-Release Respiratory Tablets and Capsules

Research-driven dosage manufacturers use our material to develop controlled release formulations that provide prolonged symptom relief. Techniques include matrix-forming or coated particle encapsulation, employing specialty excipients to modulate drug release over 6–12 hours. In-process checks verify dissolution profiles and batch reproducibility, as required for regulatory submission and market authorization.

Industry compliance standards

• USP General Chapter <711> Dissolution
• Ph. Eur. Sustained Release Specifications
• FDA New Drug Application (NDA) Guidance for Modified-Release Dosage Forms
• ICH Q8(R2) Pharmaceutical Development

Typical usage ratio

• 10–60 mg per unit, adjusted for desired release kinetics and per therapeutic indication requirements

Downstream process integration

• Wet or dry granulation with delay matrix formers, followed by tablet compaction or encapsulation; film coating with semipermeable polymers or inclusion in multiparticulate capsules

Final product types

• Extended-release antitussive tablets
• Modified-release hard gelatin capsules

5. Combination Cough and Cold Powders for Reconstitution

Producers of single-serve sachet medications employ our ingredient in combination with other actives such as paracetamol, phenylephrine, or antihistamines, enabling end-users to reconstitute powdered blends at home. The raw material requires thorough blending with flavor, stabilizer, and anti-caking agents, and precise sachet dosing to ensure compliance with local maximum single-dose and daily exposure regulations.

Industry compliance standards

• USP/NF Monographs for Oral Powders
• European Pharmacopoeia standards for Combination Cold Remedies (Ph. Eur. 2.9.38)
• Regulatory restrictions on maximum active content set by each country’s OTC classification
• GMP packaging and labeling requirements for unit-dose formats

Typical usage ratio

• 5–30 mg per sachet, typically within 0.05–0.15% w/w of total powder blend, determined by total active combination and target demographic

Downstream process integration

• High-speed powder blending lines; direct fill on automated sachet lines calibrated for low-dust, accurate metering; stability-tested for moisture ingress

Final product types

• Cough and cold powder sachets for oral solution
• Multicomponent hot drink mixes with flavor masking

6. Film-Coated Cough Suppressant Caplets

Pharmaceutical manufacturers apply our raw material as the active phase in film-coated caplet production, offering an easy-to-swallow oral format. Substantial process controls span core tablet blending, shaping, and a final film-coating step, where the selection of coating polymers ensures dose site release and compliance with product stability profiles for long-term storage.

Industry compliance standards

• USP/NF Standards for Coated Tablets
• FDA 21 CFR 111 for Dietary Supplements if positioned as self-care products
• ICH Q1A(R2) Stability Testing Guidelines
• Local Ministry of Health finished product registration requirements

Typical usage ratio

• 15–30 mg per caplet, forming 0.1–0.3% by weight, with ratio adjusted per dissolution and bioequivalence study findings

Downstream process integration

• Blended with excipients and lubricants, compacted, and shaped via caplet tooling; film-coating with aqueous or solvent-based polymers in perforated pan, followed by critical quality attribute testing

Final product types

• Antitussive caplets (film-coated or sugar-coated)
• Combination relief caplets for multi-symptom cold therapy